Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Mar 31, 2022 (5 years ago)

Janumet (sitagliptin and metformin HCl) (Sitagliptin and Metformin Hydrochloride)

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Presence of foreign substance: Presence of stainless steel particulates in tablets.

Cause type: Particulate / foreign matter

Visible foreign particles - glass, metal, fibers or other material - found in the product. Particles can enter from equipment wear, containers or the process, and are dangerous in injectables. All particulate / foreign matter recalls.

What was recalled

Janumet (sitagliptin and metformin HCl) tablets, 50 mg/500 mg, 14-count bottle, packaged as 2 bottles per carton , Sample-Not For Sale, Rx Only, Manufactured for Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. Whitehouse Station, NJ 08889, USA, by Patheon Puerto Rico, Inc. Manati, Puerto Rico, 00674 Bottle (NDC 0006-0575-02), Carton (NDC 0006-0575-03)

Affected NDCs 0006-0575-02 0006-0575-03

Compare with the code on your package — it is the most precise check available.

Drug: Metformin Category: Diabetes Medication

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Janumet
SITAGLIPTIN and METFORMIN HYDROCHLORIDE
NDC 00006-0575
SITAGLIPTIN PHOSPHATE 50 mg/1; METFORMIN HYDROCHLORIDE 500 mg/1 Tablet, Film Coated
Oral
Merck Sharp & Dohme LLC Rx
Recalling firm
Merck Sharp & Dohme CORP
NDC code
0006-0575-02
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0746-2022 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Metformin recalls

See all
Class II · Moderate risk

Synjardy XR Tablets

CGMP Deviations: An incorrect detergent was used and the required swab sampling was not performed on a production hopper that had previously been used for a different product.

Ongoing cGMP deviation Boehringer Ingelheim Pharmaceuticals, Inc. D-0657-2026

Other recalls by Merck Sharp & Dohme CORP

All 2022 recalls
Class II · Moderate risk

Noxafil Powdermix

Presence of particulate matter: potential presence of metal particulates in the product.

Ongoing Particulate / foreign matter Merck Sharp & Dohme LLC NDC 0085-2224-02 D-0242-2026
Class II · Moderate risk

Merck Emend

Presence of particulate matter: potential presence of metal particulates in the product.

Ongoing Particulate / foreign matter Merck Sharp & Dohme LLC NDC 0006-3066-03 D-0241-2026
Class II · Moderate risk

Zerbaxa (ceftolozane and tazobactam)

Lack of assurance of sterility: The results of sterility tests of seven batches of product were out of specification. Five of these batches tested positive for Ralstonia pickettii and two batches produced turbid results that could not be further identified. While all product distributed to the market has met the registered specifications for release, including for sterility, it was manufactured on the same equipment as the affected batches.

Terminated Sterility / contamination Merck Sharp & Dohme NDC 67919-030-01 D-0176-2021